Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

The two chemokines, monocyte chemoattractant protein (MCP)-1 and γ-interferon inducible protein (IP)-10, are thought to be involved in the pathogenesis of multiple sclerosis (MS). We measured MCP-1 and IP-10 levels in serum and CSF samples from 38 acute and 25 stable MS patients and from 40 controls. The latter consisted in patients with other inflammatory neurological diseases (OIND) or with non-inflammatory neurological diseases, and healthy controls. CSF MCP-1 levels exceeded those found in serum in all the patients studied as well as in healthy controls. CSF MCP-1 levels were significantly lower in acute MS [468±(S.E.M.) 18 pg/ml] than in stable MS (857±104 pg/ml). When detectable, serum and CSF IP-10 levels were significantly higher in acute MS (serum 331±66 pg/ml; CSF 118±16 pg/ml) than in stable MS (serum 69±7 pg/ml; CSF 25±2 pg/ml). Among OIND patients, those with HIV-1-associated dementia showed high serum and CSF levels of both MCP-1 and IP-10. Those with encephalitis showed high serum and CSF levels of IP-10 and CSF mononuclear pleiocytosis. We also evaluated the effects of 6-methylprednisolone or IFN-β1a therapy on circulating MCP-1 and IP-10 levels. Neither MCP-1 nor IP-10 post-therapy levels varied significantly from baseline values. Our findings suggest that (a) MCP-1 could be constitutively produced within the brain; (b) MCP-1 and IP-10 CSF levels in acute MS vary significantly from those in stable MS, and these variations are inverse; and (c) current MS therapies do not modify circulating levels of MCP-1 and IP-10.

Original languageEnglish
Pages (from-to)192-198
Number of pages7
JournalJournal of Neuroimmunology
Volume115
Issue number1-2
DOIs
Publication statusPublished - Apr 2 2001

Fingerprint

Immunomodulation
Chemokine CCL2
Acute Disease
Multiple Sclerosis
Serum
Proteins
Chemokine CXCL10
Methylprednisolone
Encephalitis
Chemokines
Dementia
HIV-1
Therapeutics

Keywords

  • Cerebrospinal fluid
  • Chemokines
  • Glucocorticoids
  • Inflammation
  • Interferon-beta
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

@article{b4c90ceff3e04cbaa31ac52c9aa9f859,
title = "Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies",
abstract = "The two chemokines, monocyte chemoattractant protein (MCP)-1 and γ-interferon inducible protein (IP)-10, are thought to be involved in the pathogenesis of multiple sclerosis (MS). We measured MCP-1 and IP-10 levels in serum and CSF samples from 38 acute and 25 stable MS patients and from 40 controls. The latter consisted in patients with other inflammatory neurological diseases (OIND) or with non-inflammatory neurological diseases, and healthy controls. CSF MCP-1 levels exceeded those found in serum in all the patients studied as well as in healthy controls. CSF MCP-1 levels were significantly lower in acute MS [468±(S.E.M.) 18 pg/ml] than in stable MS (857±104 pg/ml). When detectable, serum and CSF IP-10 levels were significantly higher in acute MS (serum 331±66 pg/ml; CSF 118±16 pg/ml) than in stable MS (serum 69±7 pg/ml; CSF 25±2 pg/ml). Among OIND patients, those with HIV-1-associated dementia showed high serum and CSF levels of both MCP-1 and IP-10. Those with encephalitis showed high serum and CSF levels of IP-10 and CSF mononuclear pleiocytosis. We also evaluated the effects of 6-methylprednisolone or IFN-β1a therapy on circulating MCP-1 and IP-10 levels. Neither MCP-1 nor IP-10 post-therapy levels varied significantly from baseline values. Our findings suggest that (a) MCP-1 could be constitutively produced within the brain; (b) MCP-1 and IP-10 CSF levels in acute MS vary significantly from those in stable MS, and these variations are inverse; and (c) current MS therapies do not modify circulating levels of MCP-1 and IP-10.",
keywords = "Cerebrospinal fluid, Chemokines, Glucocorticoids, Inflammation, Interferon-beta, Multiple sclerosis",
author = "Diego Franciotta and Gianvito Martino and Elisabetta Zardini and Roberto Furlan and Roberto Bergamaschi and Laura Andreoni and Vittorio Cosi",
year = "2001",
month = "4",
day = "2",
doi = "10.1016/S0165-5728(01)00261-2",
language = "English",
volume = "115",
pages = "192--198",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies

AU - Franciotta, Diego

AU - Martino, Gianvito

AU - Zardini, Elisabetta

AU - Furlan, Roberto

AU - Bergamaschi, Roberto

AU - Andreoni, Laura

AU - Cosi, Vittorio

PY - 2001/4/2

Y1 - 2001/4/2

N2 - The two chemokines, monocyte chemoattractant protein (MCP)-1 and γ-interferon inducible protein (IP)-10, are thought to be involved in the pathogenesis of multiple sclerosis (MS). We measured MCP-1 and IP-10 levels in serum and CSF samples from 38 acute and 25 stable MS patients and from 40 controls. The latter consisted in patients with other inflammatory neurological diseases (OIND) or with non-inflammatory neurological diseases, and healthy controls. CSF MCP-1 levels exceeded those found in serum in all the patients studied as well as in healthy controls. CSF MCP-1 levels were significantly lower in acute MS [468±(S.E.M.) 18 pg/ml] than in stable MS (857±104 pg/ml). When detectable, serum and CSF IP-10 levels were significantly higher in acute MS (serum 331±66 pg/ml; CSF 118±16 pg/ml) than in stable MS (serum 69±7 pg/ml; CSF 25±2 pg/ml). Among OIND patients, those with HIV-1-associated dementia showed high serum and CSF levels of both MCP-1 and IP-10. Those with encephalitis showed high serum and CSF levels of IP-10 and CSF mononuclear pleiocytosis. We also evaluated the effects of 6-methylprednisolone or IFN-β1a therapy on circulating MCP-1 and IP-10 levels. Neither MCP-1 nor IP-10 post-therapy levels varied significantly from baseline values. Our findings suggest that (a) MCP-1 could be constitutively produced within the brain; (b) MCP-1 and IP-10 CSF levels in acute MS vary significantly from those in stable MS, and these variations are inverse; and (c) current MS therapies do not modify circulating levels of MCP-1 and IP-10.

AB - The two chemokines, monocyte chemoattractant protein (MCP)-1 and γ-interferon inducible protein (IP)-10, are thought to be involved in the pathogenesis of multiple sclerosis (MS). We measured MCP-1 and IP-10 levels in serum and CSF samples from 38 acute and 25 stable MS patients and from 40 controls. The latter consisted in patients with other inflammatory neurological diseases (OIND) or with non-inflammatory neurological diseases, and healthy controls. CSF MCP-1 levels exceeded those found in serum in all the patients studied as well as in healthy controls. CSF MCP-1 levels were significantly lower in acute MS [468±(S.E.M.) 18 pg/ml] than in stable MS (857±104 pg/ml). When detectable, serum and CSF IP-10 levels were significantly higher in acute MS (serum 331±66 pg/ml; CSF 118±16 pg/ml) than in stable MS (serum 69±7 pg/ml; CSF 25±2 pg/ml). Among OIND patients, those with HIV-1-associated dementia showed high serum and CSF levels of both MCP-1 and IP-10. Those with encephalitis showed high serum and CSF levels of IP-10 and CSF mononuclear pleiocytosis. We also evaluated the effects of 6-methylprednisolone or IFN-β1a therapy on circulating MCP-1 and IP-10 levels. Neither MCP-1 nor IP-10 post-therapy levels varied significantly from baseline values. Our findings suggest that (a) MCP-1 could be constitutively produced within the brain; (b) MCP-1 and IP-10 CSF levels in acute MS vary significantly from those in stable MS, and these variations are inverse; and (c) current MS therapies do not modify circulating levels of MCP-1 and IP-10.

KW - Cerebrospinal fluid

KW - Chemokines

KW - Glucocorticoids

KW - Inflammation

KW - Interferon-beta

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0035795017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035795017&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(01)00261-2

DO - 10.1016/S0165-5728(01)00261-2

M3 - Article

C2 - 11282170

AN - SCOPUS:0035795017

VL - 115

SP - 192

EP - 198

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -